Search Within

Vincent Miller

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (31)
Groups
  1. GSK Faculty (64)
  2. Human Oncology and Pathogenesis Program (64)
  3. Tow Center for Developmental Oncology (TCDO) (62)
  4. Department of Pathology and Laboratory Medicine (61)
  5. Department of Medicine (59)
  6. Solid Tumor Oncology Division (55)

More Groups

People
  1. Marc Ladanyi (59)
  2. Mark Kris (46)
  3. Gregory Riely (44)
  4. William Pao (33)
  5. Maureen Zakowski (29)
  6. Maria Arcila (21)

More People

Years
  1. 2019 (1)
  2. 2016 (1)
  3. 2015 (2)
  4. 2014 (3)
  5. 2013 (1)
  6. 2012 (7)

More Years

Publications
  1. Journal of Clinical Oncology (21)
  2. Clinical Cancer Research (12)
  3. Journal of Molecular Diagnostics (5)
  4. Journal of Thoracic Oncology (4)
  5. Laboratory Investigation (3)
  6. Modern Pathology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (21)
  2. American Association for Cancer Research (16)
  3. Elsevier Science, Inc. (5)
  4. Nature Publishing Group (5)
  5. Elsevier Inc. (4)
  6. Nature Research (3)

More Publishers

Results (64)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas
    Journal Article

    Paik, P. K.; Johnson, M. L.; D'Angelo, S. P.; Sima, C. S.; Ang, D.; Dogan, S.; Miller, V. A.; Ladanyi, M.; Kris, M. G.; Riely, G. J.
    Cancer (2012)

    Fulltext@MSK | Save
  • Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
    Journal Article

    Zhang, Z.; Lee, J. C.; Lin, L.; Olivas, V.; Au, V.; Laframboise, T.; Abdel-Rahman, M.; Wang, X.; Levine, A. D.; Rho, J. K.; more...
    Nature Genetics (2012)

    Fulltext@MSK | Save
  • Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
    Journal Article

    Ohashi, K.; Sequist, L. V.; Arcila, M. E.; Moran, T.; Chmielecki, J.; Lin, Y. L.; Pan, Y.; Wang, L.; de Stanchina, E.; Shien, K.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2012)

    Fulltext@MSK | Save
  • Screening for germline EGFR T790M mutations through lung cancer genotyping
    Journal Article

    Oxnard, G. R.; Miller, V. A.; Robson, M. E.; Azzoli, C. G.; Pao, W.; Ladanyi, M.; Arcila, M. E.
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • EGFR exon 19 insertions: A new family of sensitizing EGFR mutations in lung adenocarcinoma
    Journal Article

    He, M.; Capelletti, M.; Nafa, K.; Yun, C. H.; Arcila, M. E.; Miller, V. A.; Ginsberg, M. S.; Zhao, B.; Kris, M. G.; Eck, M. J.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Meeting Abstract

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; Miller, V. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Response to EGFR TKIs in never smokers with stage IV EGFR mutant squamous cell carcinoma of the lung (SQCC)
    Meeting Abstract

    Paik, P. K.; Rekhtman, N.; Riely, G. J.; Miller, V. A.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Journal Article

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Sima, C. S.; Kass, S. L.; Riely, G. J.; Pao, W.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosinekinase inhibitors in lung cancer
    Journal Article

    Oxnard, G. R.; Arcila, M. E.; Chmielecki, J.; Ladanyi, M.; Miller, V. A.; Pao, W.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling
    Journal Article

    Chmielecki, J.; Foo, J.; Oxnard, G. R.; Hutchinson, K.; Ohashi, K.; Somwar, R.; Wang, L.; Amato, K. R.; Arcila, M.; Sos, M. L.; more...
    Science Translational Medicine (2011)

    Fulltext@MSK | Save